High Insider Ownership Stocks Retail Investors Are Watching For Growth

Oil prices remain elevated as energy supply risks keep pressure on inflation expectations. That backdrop keeps investors focused on companies that can grow through uncertainty and where insiders have meaningful skin in the game. The Fast Growing Stocks With High Insider Ownership screener looks for exactly that mix. This article highlights three stocks from the screener that stand out and explains why each might deserve your attention now.

The stocks covered below are just a starting sample, and the full screen surfaced 99 more companies with equally compelling growth and insider ownership stories that are not covered here. If you want to identify and analyze your own potential high conviction ideas from this universe, head straight to the Fast Growing Stocks With High Insider Ownership screener.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is an Australia based gold company focused on exploring, developing and operating gold assets in West Africa, with its flagship Bankan Gold project in Guinea supported by producing mines at Kiniero and Nampala.

Market Cap: A$3.8b

Predictive Discovery gives you direct exposure to West African gold production at scale, with two operating mines and the large Bankan project under way, backed by a 9.5 million ounce resource and 4.5 million ounces of reserves. The company sits in an unusual position for a growth stock. Analysts expect very strong revenue and earnings growth over the next few years and see material upside to their A$1.49 consensus price target, yet the shares currently trade well below some modelled fair value estimates. The trade off is real. There is a tight cash runway, reliance on external borrowing, emerging market jurisdiction risk and a history of shareholder dilution. If management can deliver on production guidance and permitting, the risk reward profile may be of interest to growth focused investors.

Predictive Discovery sits at the crossroads of large scale West African gold potential and tight funding risk. Before you rely on headline growth forecasts, review the 2 key rewards and 3 important warning signs (2 are major!).

Build your own high growth, high conviction shortlist

Predictive Discovery and the other two stocks in this article all came from the same screener, but the real edge is shaping filters around your own priorities. Use our flexible Screener to combine growth, valuation, balance sheet and risk filters, or start with one of our curated Investing Ideas.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals is a commercial stage biopharmaceutical company that develops and sells radiopharmaceutical products that help doctors precisely image and treat cancers, such as prostate, kidney and brain tumours, using targeted radioactive agents.

Operations: Telix Pharmaceuticals generates most of its roughly US$804 million revenue from Precision Medicine at about US$622 million, with additional contributions of about US$245 million from Manufacturing Solutions and about US$9 million from Therapeutics, partly offset by inter segment eliminations.

Market Cap: A$5.7b

Telix Pharmaceuticals sits at the intersection of commercial revenue from prostate cancer imaging agents like Illuccix and Gozellix and a late stage pipeline that targets some of the hardest to treat tumours. It is a company that is already generating hundreds of millions in sales, issuing FY2026 guidance above US$1b, while trading at a P/S multiple well below many Australian biotech peers. The flip side is real risk. The stock has already gone through a sharp drawdown, there is an SEC subpoena over disclosures, pricing pressure in PSMA imaging and heavy R&D and manufacturing spend while the company remains loss making. If Telix can convert Phase 3 trials such as ProstACT Global and LUTEON into approved therapies, the mix of current cash flow and future optionality may be worth a closer look.

Telix Pharmaceuticals appears to combine real revenue with late-stage cancer pipeline potential that many investors may still be pricing cautiously. Get the full context in the analysis report for Telix Pharmaceuticals

GemLife Communities Group (ASX:GLF)

Overview: GemLife Communities Group develops, builds, owns and operates resort style land lease communities for over 50s across Australia, combining new home sales with ongoing community management and amenities such as clubhouses, gardens and leisure facilities.

Operations: GemLife Communities Group generates most of its A$281.7 million revenue from Development at about A$259.8 million, with around A$21.9 million from Community Operations, all in Australia.

Market Cap: A$1.7b

GemLife Communities Group taps into Australia’s growing over 50s downsizer trend, backed by a pipeline of around 8,300 homesites and a vertically integrated model that can help protect building margins and control quality. Recurring, inflation linked site rental fees and a long dated, largely funded development pipeline give the business a mix of upfront and ongoing income that many investors look for in real estate linked stocks. Yet earnings declined over the past year, return on equity is still low and the company relies heavily on external debt while trading on a P/E well above sector averages. With first half 2026 results due on 24 August and a 2026 distribution already flagged, GemLife is a stock where growth expectations and execution risk sit side by side.

GemLife Communities Group appears to be a growth story that many investors still approach with caution, given its P/E and debt load. Get the full picture on whether that mix holds up in the 4 key rewards and 2 important warning signs (1 is major!)

Seeking Alternatives Before The Crowd Moves

Fresh opportunities can move from quiet to flying quickly. Some potential breakouts are still under the radar for now. Do not wait until momentum is already established; consider acting before trends are widely recognized.

• Target dependable income streams while others focus on the headlines and work through a curated set of income ideas in the 4 dividend fortresses.
• Look for potential growth breakouts that may be hiding in plain sight and run your own checks across a carefully filtered group in the 12 high quality undiscovered gems.
• Prepare for major infrastructure themes by reviewing companies involved in tomorrow's grid with the focused 37 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com